Quick Answer
TELA Bio, Inc. reported Cash and Equivalents of $50.84 million for fiscal year 2025.
TELA Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $50.84M | -3.5% |
| 2024 | $52.67M | +12.7% |
| 2023 | $46.73M | +11.2% |
| 2022 | $42.02M | -4.4% |
| 2021 | $43.93M | -40.9% |
| 2020 | $74.39M | +64.2% |
| 2019 | $45.30M | +162.2% |
| 2018 | $17.28M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.71M | +71.7% | -15.0% |
| June 30, 2025 | $34.98M | +32.0% | -18.3% |
| March 31, 2025 | $42.83M | +15.3% | -18.7% |
| December 31, 2024 | $52.67M | +12.7% | +204.4% |
| September 30, 2024 | $17.30M | -70.3% | -34.7% |
| June 30, 2024 | $26.50M | -59.4% | -28.7% |
| March 31, 2024 | $37.14M | +23.3% | -20.5% |
| December 31, 2023 | $46.73M | +11.2% | -19.7% |
- TELA Bio, Inc. showed a decrease of -3.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, TELA Bio, Inc.’s cash and equivalents has grown by 194.3% (from $17.28 million to $50.84 million).
- The most recent figure is from TELA Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: